KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Idexx Laboratories (IDXX) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Idexx Laboratories (IDXX) over the last 17 years, with Q3 2025 value amounting to $421.9 million.

  • Idexx Laboratories' Cost of Revenue rose 1116.72% to $421.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 562.13%. This contributed to the annual value of $1.5 billion for FY2024, which is 323.55% up from last year.
  • Idexx Laboratories' Cost of Revenue amounted to $421.9 million in Q3 2025, which was up 1116.72% from $414.7 million recorded in Q2 2025.
  • In the past 5 years, Idexx Laboratories' Cost of Revenue registered a high of $421.9 million during Q3 2025, and its lowest value of $306.9 million during Q1 2021.
  • In the last 5 years, Idexx Laboratories' Cost of Revenue had a median value of $367.5 million in 2023 and averaged $362.6 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first surged by 3042.94% in 2021, then tumbled by 73.04% in 2022.
  • Over the past 5 years, Idexx Laboratories' Cost of Revenue (Quarter) stood at $344.7 million in 2021, then dropped by 0.3% to $343.6 million in 2022, then rose by 9.25% to $375.4 million in 2023, then increased by 2.18% to $383.6 million in 2024, then increased by 9.97% to $421.9 million in 2025.
  • Its Cost of Revenue was $421.9 million in Q3 2025, compared to $414.7 million in Q2 2025 and $375.0 million in Q1 2025.